Donate For Public and Patients Store Search

U034 - Emerging Non-transplant Procedures and Drug Delivery for the Management of Complex Alopecias

Saturday, March 2; 7:30 AM - 8:30 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe the available evidence for the use of platelet rich plasma, microneedling and laser-assisted drug delivery for the management of alopecia.
  • Describe platelet rich plasma preparation techniques.

Description

This session will focus on the rise of emerging minimally invasive procedures for the management of alopecia. The use of platelet rich plasma for hair disease will be reviewed in detail including evidence in the literature, product preparation, centrifuge characteristics, and current research. Microneedling will be reviewed along with available evidence. Evidence based literature and research trends in laser assisted drug delivery for the management of refractory alopecia will also be defined.

Disclosures

  • Farah, Ronda S., MD: Capillus Laser Caps – O(EQ); Early Sullivan Wright Gizer & McRae LLP – C(NC); Eclipse Medical – O(Grants/Research Funding); Gilead Sciences – SH(NC); HairMax – O(EQ); Inovio Pharmaceuticals, Inc – SH(NC); LaserCap – O(EQ); Pfizer Inc. – SH(NC); Syneron Candela – O(Grants/Research Funding); Theradome – O(EQ); WEN – I(Grants/Research Funding);
  • Hordinsky, Maria K., MD: Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); Astellas Pharma US, Inc – I(Grants/Research Funding); Concert Pharmaceuticals – C(Fees); Incyte Corporation – O(Grants/Research Funding); Procter & Gamble Company – C(H); UpToDate, Inc – I(Grants/Research Funding);
  • Junqueira Bertin, Ana, MD: no financial relationships exist with commercial interests.
  • Junqueira, Ana Lucia, MD: no financial relationships exist with commercial interests.
  • Rogers, Nicole Elaine, MD: Johnson & Johnson Consumer Products Company – C(Fees); ParaPRO LLC – SP(H); Redken – C(Fees); Regimen MD – SH(NC);
  • Sadick, Neil S., MD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Allergan, Inc. – C(H), O(H); Almirall – C(H); AnaptysBio – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Carma Laboratories, Inc – O(H); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc. – C(H); Derm Advance – SH(SO); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), O(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(H); Incyte Corporation – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Pfizer Inc. – I(Grants/Research Funding); Philips Healthcare – I(Grants/Research Funding); Prescriber's Choice – O(H); Regeneron – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Slender Medical Ltd. – SH(SO); Sol-Gel Technologies – I(Grants/Research Funding); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), I(Grants/Research Funding), SP(H);
Schedule
Saturday, March 2
7:30 AM
Dr. Farah / Introduction to Session-Welcome
7:32 AM
Dr. Hordinsky / Platelet Rich Plasma in Alopecia: evidence, clinical applications and future directions
7:44 AM
Dr. Sadick / Platelet Rich Plasma for the Management of Alopecia: pearls for the clinician
7:56 AM
Dr. Rogers / The use of microneedling as a novel clinical tool for the management of alopecia
8:08 AM
Dr. Farah, Junqueira, and Junqueira Bertin / Trends in Drug Delivery in Alopecia: an evidence based review
8:20 AM
All faculty / Questions & Answers
Event Details
  • Date
    Saturday, March 2
  • Time
    7:30 AM - 8:30 AM
  • Location
    Room 146A
  • CME Credits
    1.00
  • Type
    New
Directors/Co-Directors
  • Ronda S. Farah, MD, FAAD
Speakers
  • Ana Junqueira Bertin, MD
  • Ana Lucia Junqueira, MD
  • Maria K. Hordinsky, MD, FAAD
  • Neil S. Sadick, MD, FAAD
  • Nicole Elaine Rogers, MD, FAAD